Larry Hong represents leading global companies in complex business disputes and class actions, often with a cross-border component, in federal and state courts. He represents financial institutions, publicly traded companies, and individuals across a variety of industries, including technology, healthcare, and consumer products. Mr. Hong also represents clients in matters outside of litigation, including arbitration and mediation.
Mr. Hong was previously a judicial intern at the United States District Court for the Southern District of New York and an associate at Latham’s London office.
Experience
Mr. Hong has achieved favorable outcomes in the following recent representative matters:
The underwriters of Miniso’s IPO in a securities class action, resulting in complete dismissal (SDNY 2024)
Sinovac Biotech Ltd. in shareholder litigation concerning its 2018 PIPE transaction, resulting in dismissal with prejudice (D. Mass. 2023)
A Chinese internet security company in a securities class action concerning its take-private transaction, resulting in dismissal of over 99% of claimed damages (SDNY 2023)
An exercise equipment company in defeating class certification and achieving a partial dismissal of claims in consumer class action alleging false advertising (SDNY 2023)
Mallinckrodt Pharmaceuticals in reorganizing under chapter 11, following numerous contested maters and hotly contested confirmation hearing (Bankr. D. Del. 2022)
Qualifications
Bar Qualification
New York
Education
JD, Duke University School of Law, 2020
MA in Economic Law, Sciences Po Paris, 2020
BA in Political Science & Philosophy, Columbia University, 2017
A Latham team received recognition for securing a victory for Goldman Sachs and BofA Securities in a shareholder class action arising out of global retailer MINISO’s October 2020 IPO.
Despite objections from the U.S. Trustee, the SEC, the state of Rhode Island and others, Latham’s Chris Harris and Betsy Marks were able to get judicial sign-off on the pharma company’s reorganization plan, including a US$1.7 billion settlement of opioid-related litigation.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.